From Wikipedia, the free encyclopedia
  (Redirected from GSK744)
Jump to: navigation, search
Cabotegravir (GSK744).svg
Cabotegravir ball-and-stick model.png
3D model (JSmol)
Molar mass 405.36 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N (what is YesYN ?)
Infobox references

Cabotegravir (USAN[1] and INN[2]) (also known as S/GSK1265744 or GSK744) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir.[3] In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long biological half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.[4]

Cabotegravir is being examined in the clinical trial HPTN 083.


  1. ^ "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014. 
  2. ^ "WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014. 
  3. ^ Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819. 
  4. ^ PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.